HBV Forum 3 was held on October 24, 2017 in Washington DC and was attended by 98 participants, 87 in person and 11 remotely. 

Materials 

Agenda

List of Participants

Meeting Evaluation 

Meeting Summary of Procedures

Presentations

• Welcome and Introductory Remarks
  Veronica Miller and Pedro Goicochea
• Current FDA Perspective on HBV Drug Development
  Poonam Mishra
• FDA Perspective on HBV Diagnostic Devices
  Kathleen Whitaker
• Quantitative Serum HBsAg Assay Validation for U.S. Patient Testing
  Robert Gish
• Implications of HBsAg from Integrated DNA for Clinical Trial Design
  Bruce Given
• HBV Next Generation Sequencing
  Leen-Jan van Doorn
• Diagnostics and Biomarkers Working Group Updates
  Gavin Cloherty
• Surrogate Endpoints Working Group Updates
  Oliver Lenz 
• Treatment Combinations Working Group Updates
  Bruce Given
• Road Map of Research Priorities for HBV Cure
• Tim Block
• International Coalition to Eliminate HBV
• Peter Revill